Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · IEX Real-Time Price · USD
1.330
+0.070 (5.56%)
At close: Apr 19, 2024, 4:00 PM
1.360
+0.030 (2.26%)
After-hours: Apr 19, 2024, 5:02 PM EDT
Company Description
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States.
Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex.
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Dr. Mark Manfredi Ph.D. |
Contact Details
Address: 50 Northern Ave. Boston, Massachusetts 02210 United States | |
| Phone | 857-343-8292 |
| Website | ikenaoncology.com |
Stock Details
| Ticker Symbol | IKNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G108 |
| ISIN Number | US45175G1085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Financial Officer and Head of Corporate Development |
| Bob Lally | Senior Vice President of Finance and Operations |
| Srividya Subramanian Esq., Ph.D. | Vice President and Deputy General Counsel |
| Samantha Vuksanic | Head of Human Resources |
| Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Navin Parwani M.S. | Vice President and Head of Quality |
| David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
| Dr. Caroline Germa M.D. | Chief Medical Officer |
| Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 18, 2024 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |